Asian shares are mixed after S&P 500 and Nasdaq composite pull back from their all-time highs
An announcement over the weekend by U.S. President Donald Trump that he plans 30% tariffs on goods from Mexico and the European Union had scant immediate impact, as analysts said they expected progress toward trade deals before an Aug. 1 deadline.
The Mexican peso weakened slightly against the dollar, trading at 18.6 pesos to the dollar.
Chinese shares advanced after the government reported that exports rose last month as a truce in a tariffs war prompted a surge in orders ahead of an Aug. 12 deadline for reaching a new trade deal with Washington.
Hong Kong's Hang Seng gained 0.5% to 24,253.18, while the Shanghai Composite index also was up 0.5%, at 3,526.75.
Tokyo's Nikkei 225 index slipped 0.3% to 39,459.20, while the Kospi in South Korea jumped 0.8% to 3,200.25.
In Australia, the S&P/ASX 200 was little changed at 8,577.80.
Taiwan's benchmark lost 2.3%.
On Friday, a modest pullback for U.S. stocks left major stock indexes on Wall Street in the red for the week.
The S&P 500 closed 0.3% lower, at 6,259.75, a day after setting a record high.
The Dow Jones Industrial Average dropped 0.6% to 44,371.51, and the Nasdaq composite gave up 0.2% to 20,585.53 after drifting between small gains and losses much of the day. The tech-heavy index was coming off its own all-time high on Thursday.
The selling capped an uneven week in the market as Wall Street kept an eye on the Trump administration's rollout of new tariff threats against trading partners like Canada and looked ahead to the upcoming corporate earnings reporting season.
Trump said in a letter Thursday that he will raise taxes on many imported goods from Canada to 35%, deepening the rift between the longtime North American allies. The letter to Canadian Prime Minister Mark Carney was an aggressive increase to the top 25% tariff rates that Trump first imposed in March.
The administration had initially set Wednesday as a deadline for countries to make deals with the U.S. or face heavy increases in tariffs. But with just two trade deals announced since April, one with the United Kingdom and one with Vietnam, the window for negotiations has been been extended to Aug. 1.
Trump also floated this week that he would impose tariffs of as much as 200% on pharmaceutical drugs and place a 50% tariff on copper imports, matching the rates charged on steel and aluminum.
The initial rollout of Trump's tariff policies in the spring roiled financial markets. But they have been relatively stable in recent weeks, suggesting investors have adjusted to the unpredictability of his sudden policy shifts.
Markets are set to shift their focus to quarterly earnings over the next few weeks. JPMorgan Chase, Wells Fargo and Citigroup are among big banks due to report their results on Tuesday.
Shares in aviation company Red Cat Holdings jumped 26.4% Friday after Defense Secretary Pete Hegseth issued orders aimed at ramping up production and deployment of drones.
Bitcoin climbed to another all-time high, rising 3.6% early Monday to $122,065, according to Coindesk.
Bitcoin's price has jumped amid bullish momentum across risk assets and coincides with Nvidia's surge to a $4 trillion valuation. The U.S. Congress' Crypto Week starts Monday. Lawmakers will debate a series of bills that could define the regulatory framework for the industry.
In other dealings early Monday, U.S. benchmark crude oil gained 9 cents to $68.54 per barrel. Brent crude, the international standard, was up 10 cents at $70.46 per barrel.
The dollar slipped to 147.36 Japanese yen from 147.38 yen. The euro fell to $1.1659 from $1.1692.
___
AP Business Writer Alex Veiga contributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 minutes ago
- Yahoo
Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis
SOUTH SAN FRANCISCO, Calif., July 15, 2025--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that the Division of Hepatology and Nutrition of the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on the completed PORTOLA Phase 2a clinical trial evaluating zetomipzomib, a first-in-class selective immunoproteasome inhibitor, in patients with autoimmune hepatitis (AIH). "We are pleased that the FDA has lifted the partial clinical hold on zetomipzomib in AIH after their review of our comprehensive safety assessment of the zetomipzomib program," said Chris Kirk, PhD, CEO and co-founder of Kezar. "We continue to believe that zetomipzomib has the potential to positively transform the lives of patients living with AIH. We look forward to engaging with the FDA to align on the design of the next clinical trial of zetomipzomib in AIH." Although Kezar has suspended development of zetomipzomib in lupus nephritis (LN) to focus on AIH, the company met with the Independent Data Monitoring Committee (IDMC) for the previously terminated PALIZADE clinical trial to review the safety profile of zetomipzomib. The IDMC has provided Kezar with recommendations for conducting future clinical trials in LN. Based on this feedback and internal analysis of safety data across all clinical studies involving zetomipzomib, Kezar plans to respond to the FDA Division of Rheumatology and Transplant Medicine with a request to lift the clinical hold on zetomipzomib in LN. About Zetomipzomib Zetomipzomib is a novel, first-in-class, selective immunoproteasome inhibitor with broad therapeutic potential across multiple autoimmune diseases. Preclinical research demonstrates that selective immunoproteasome inhibition results in a broad anti-inflammatory response in animal models of several autoimmune diseases, while avoiding immunosuppression. Data generated from completed clinical trials provide evidence that zetomipzomib exhibits a favorable safety and tolerability profile for development in severe, chronic autoimmune diseases. About Autoimmune Hepatitis Autoimmune hepatitis (AIH) is a rare chronic disease in which the immune system attacks the liver and causes inflammation and tissue damage, severely impacting patients' physical health and quality of life. Lifelong maintenance therapy is required to avoid relapse and burdensome adverse effects. If left untreated, AIH can lead to cirrhosis, liver failure and hepatocellular carcinoma. In the United States, AIH affects approximately 100,000 individuals, with incidence rates increasing. The cause of this condition remains unclear, with females affected four times as often as males. Currently, standard of care treatment for AIH is chronic, immunosuppressive treatment with corticosteroids that frequently cause life-altering side effects, including diabetes, osteoporotic fractures and cataracts. There is a significant need for treatment regimens that reduce or remove the need for chronic immunosuppression from use of corticosteroids. About Kezar Life Sciences Kezar Life Sciences is a clinical-stage biopharmaceutical company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases. Zetomipzomib, a selective immunoproteasome inhibitor, is currently being evaluated for autoimmune hepatitis. This product candidate also has the potential to address multiple chronic immune-mediated diseases. For more information, visit and follow us on LinkedIn, Facebook, Twitter and Instagram. Cautionary Note on Forward-looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "can," "should," "expect," "believe," "potential," "anticipate" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Kezar's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause Kezar's clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the timing and outcome of regulatory submissions and interactions with the FDA, EMA or any other regulatory agencies with respect to zetomipzomib or Kezar's clinical trials, the initiation of an additional clinical trial of zetomipzomib in AIH, and expectations regarding the removal of the clinical hold of zetomipzomib in LN, and the likelihood of obtaining regulatory approval of zetomipzomib. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during clinical studies, difficulties enrolling and conducting our clinical trials, changes in expected or existing competition, changes in the regulatory environment, the uncertainties and timing of the regulatory approval process, and unexpected litigation or other disputes. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Kezar's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" contained therein. Except as required by law, Kezar assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available. View source version on Contacts Investor and Media Contact:Gitanjali JainSenior Vice President, Investor Relations and External AffairsKezar Life Sciences, Melden Sie sich an, um Ihr Portfolio aufzurufen.
Yahoo
8 minutes ago
- Yahoo
Nvidia's China Comeback Underway
Nvidia (NASDAQ:NVDA) just got word from Washington that its export licenses for H20 GPUs to China are on track. The team hopes to restart shipments soon, and investors are buzzing. That pause back in April cost roughly eight billion dollars in quarterly revenue and tipped the balance to competitors. Shares jumped five percent before the bell as traders cheered what Wedbush calls a watershed moment. Warning! GuruFocus has detected 4 Warning Signs with NVDA. This follows Jensen Huang's sit-down with President Trump at the White House, underscoring how closely Nvidia has worked with policymakers amid rising tech tensions. China accounts for about fifteen percent of Nvidia's sales. Restoring that channel could lift Wall Street estimates and fuel Nvidia's next growth wave as global AI demand keeps exploding. With both Beijing and Washington looking to ease friction, Nvidia's regained China foothold may power a broader tech rally and reaffirm Jensen Huang's lead in the AI arms race. This article first appeared on GuruFocus. Errore nel recupero dei dati Effettua l'accesso per consultare il tuo portafoglio Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati
Yahoo
11 minutes ago
- Yahoo
White House has a new take on the markets' mild tariff reaction
Markets (^GSPC, ^IXIC, ^DJI) have been brushing off President Trump's daily tariff threats. Yahoo Finance Washington Correspondent Ben Werschkul joins Market Domination host Josh Lipton to explain how the White House's read on market reactions sharply contrasts with Wall Street's view. He also discusses the president's new deal with Indonesia and what it could signal. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. markets growing less responsive to ongoing trade talks and there's different views on why that may be. For more, let's get to Yahoo Finance's Washington correspondent. That would be, of course, Ben Worskol. Ben. Hey, Josh. Yes. So this is the question, kind of one of the big questions of the month for markets is sort of why are markets shrugging off this, these tariff threats that I'm on with you pretty much every day to outline, they come kind of every day from Trump. It's a nuanced question for sure. Our colleague Josh Shafer has a smart look at the kind of China aspect of this. But what I'm looking at for a story tomorrow in Yahoo Finance is the White House view of this. And this is important for traders to know because it's essentially 180 degrees away from most of what you're going to hear on Wall Street. The White House case, which has, we've seen in evidence in recent days, and it's gotten sharper, kind of as markets continue to rise, is essentially that the signal we're getting here is that traders are okay with tariffs now. That the traders are saying that they understand what Trump is trying to do with tariffs and that the market reaction is, is, is, is, is, is reflecting that. You see a lot of skepticism from that on Wall Street, who kind of give the opposite view that traders, it's not like traders like tariffs now. They just don't believe Trump is going to follow through. But we're seeing this again and again. Treasury Secretary Scott Beson offered this morning that the markets understand what, what Trump is doing now, which is a clear contrast to April. Somebody's going to be wrong here. These are two sides, and this is, the question is kind of whether this question gets tested. The way it doesn't get tested is if Trump can follow through on different trade deals and lower rates via that route for him. We saw, we saw one pact with Indonesia today. But it does get tested if some of these, these trade deals don't go through, and then Trump is essentially empowered by this view that he, that, that, by not, by, by the market's not rising so far, maybe he can stand firm on tariffs and go forward. Put another way, does the market looking at the Taco trade essentially lessen the chance of Trump, of Trump chickening out? We're seeing some concerns on that front that maybe the markets are underpricing. You were talking about Jamie Diamond earlier. He's offered commentary on this. The markets are complacent in this. This is, this is going to be a big theme of the next few weeks as we get to this August 1st deadline. Ben, just quickly, you mentioned Indonesia there. I want your take because Trump did say he reached this deal with Indonesia. It does sound like we have, have some specifics there. Ben, what are the details? Yeah. So we have some specifics from the White House side on what this Indonesia pact brings forward today. Trump sketched it out to reporters and also on a truth social, two social posts. The headline here is a 19% tariff on Indonesian goods and from, and according to Trump, a 0% tariff on US companies trying to do business. As, as Trump put it, quote, full access to Indonesia. He added in true social that there's other aspects here, $15 billion in Indonesian purchases of US energy, four, four and a half billion dollars in American agriculture, and 50 Boeing jets. The key caveat here is that we do not have confirmation on this from the Indonesian side. This is a trend we've seen where Trump will announce a deal, and then the question is whether the other side has agreed to all the terms here. We saw a little bit of that with Vietnam. But either way, this is a clear indication that this is the sort of model he even, Trump even had a comment about this today, that this is the sort of outline of what he wants with these other deals. Essentially, somewhere around a 20% tariff on coming in, on product coming in, and then a 0% tariff on products going out. It's the sort of same parameters of what he laid out with Vietnam. So, so he's, it comes with sort of Trump is promising other trade deals again ahead of this August 1st deadline, in his view hoping to be kind of this be the, be the model going forward. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
